Format

Send to

Choose Destination
Immunity. 2016 Nov 15;45(5):958-960. doi: 10.1016/j.immuni.2016.10.033.

HIV Broadly Neutralizing Antibodies: Taking Good Care Of The 98.

Author information

1
International AIDS Vaccine Initiative, New York, NY 10004, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: devinsok@scripps.edu.
2
Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02129, USA. Electronic address: burton@scripps.edu.

Abstract

In this issue of Immunity, Huang et al. (2016) describe an exceptionally broad and potent neutralizing antibody to HIV. This antibody, N6, is capable of neutralizing up to 98% of global isolates with a potent median IC50 of 0.04 μg/mL, making it the current "best-in-class" for bNAbs targeting the CD4 binding site.

PMID:
27851923
PMCID:
PMC5378060
DOI:
10.1016/j.immuni.2016.10.033
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center